NCT04602390

Assessment of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis

A Phase 1 Study of the Safety and Tolerability of Single and Multiple Doses of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 34 (actual)
• Sponsor: Anokion SA · Industry
• Sex: All
• Age: 18 Years – 60 Years
• Healthy volunteers: Not accepted

Summary

A safety study of ANK-700 in patients with relapsing remitting multiple sclerosis. The study has two parts: Part A - first in human study in which patients receive a single dose of ANK-700 Part B - patients will receive three doses of either ANK-700 or placebo

Detailed description

Study ANK-700-01 is a Phase 1, FIH study designed to evaluate the safety and tolerability of ANK-700 in patients with relapsing remitting multiple sclerosis (rrms). An overview of the two parts and proposed dose groups is given below: Part A (SAD): Patients will receive a single dose of ANK-700. Part B (MAD): Patients will receive three doses of either ANK-700 or placebo.

Conditions

• Multiple Sclerosis (MS)
• Relapsing Remitting Multiple Sclerosis

Interventions

Type	Name	Description
DRUG	ANK-700	Intravenous (IV) infusion
DRUG	Placebo	Intravenous (IV) infusion

Timeline

• Start date: 2020-11-06
• Primary completion: 2024-04-23
• Completion: 2024-04-23
• First posted: 2020-10-26
• Last updated: 2025-05-31
• Results posted: 2025-05-31

Locations

15 sites across 1 country: United States

Regulatory

• FDA-regulated drug study